Keros Therapeutics Inc
KROSBuild a strategy around KROS
Keros Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Cash of 693M is 84% of market cap (827M) - trading near cash value with profitable operations generating 87M FCF TTM[Cash and Equivalents]
- Rare profitable biotech: 18% operating margin TTM vs industry median of 0% - shifted from cash-burn to self-funding[Operating Margin TTM]
- Revenue 5Y CAGR of 151% with 36% 1Y growth TTM - commercial traction accelerating while maintaining profitability[Total Revenue 5Y Growth TTM]
Watch Triggers
- Operating Margin TTM: Falls below 10% or turns negative — Profitability is key differentiator; margin compression signals return to cash-burn biotech model
- Cash and Equivalents: Drops below 500M without acquisition — Cash floor thesis depends on fortress balance sheet; unexpected burn destroys margin of safety
- Total Revenue 1Y Growth: Decelerates below 15% — 36% growth TTM justifies R&D spend; slowing growth questions commercial execution
Bull Case
Trading at EV of 151M with 693M cash and 87M annual FCF - effectively paying negative value for a profitable, growing biotech with active pipeline
ROE of 10.4% and ROIC of 10.1% TTM exceptional for biotech - management deploying capital productively while peers burn cash
Bear Case
Revenue concentration risk - 247M TTM likely from limited products/partnerships; single trial failure could reverse profitability
Small cap (827M) with 41M shares - any negative catalyst creates liquidity risk; biotech sentiment can gap stock below cash value
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage KROS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash fortress + profitability creates asymmetric risk/reward - downside protected by 693M cash floor
- EV of only 151M implies market pricing in minimal pipeline value
- FCF positive (87M TTM) extends runway indefinitely
- Debt/equity of 0.02 eliminates dilution pressure
R&D intensity (64% of revenue) positions for pipeline catalysts that could re-rate EV dramatically
- 157M R&D spend TTM on 247M revenue
- Self-funded trials reduce binary financing risk
- Low EV (151M) means any success is upside
Valuation Context
Caveats
Public Strategies Rankings
See how Keros Therapeutics Inc ranks across different investment strategies.
Leverage KROS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
KROS Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$304.73M | — | ||
$34.2M | — | ||
4.8 | — | ||
$244.06M | +6775.0% | — | |
$2.30 | — | ||
27.7% | +5931.8% | — | |
35.7% | +5313.2% | — | |
$105.95M | — | ||
19.9% | +61.4% | — | |
Beta 5Y (Monthly) | unknown | — |
KROS Dividend History
KROS Stock Splits
KROS SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/04/26 | 12/31/25 | 10-K | |
11/05/25 | 09/30/25 | 10-Q | |
08/06/25 | 06/30/25 | 10-Q | |
05/06/25 | 03/31/25 | 10-Q | |
02/26/25 | 12/31/24 | Unknown | |
11/06/24 | 09/30/24 | 10-Q | |
08/07/24 | 06/30/24 | 10-Q | |
05/08/24 | 03/31/24 | 10-Q | |
02/28/24 | 12/31/23 | 10-K | |
11/06/23 | 09/30/23 | 10-Q | |
08/07/23 | 06/30/23 | 10-Q | |
05/04/23 | 03/31/23 | 10-Q | |
03/03/23 | 12/31/22 | 10-K | |
11/03/22 | 09/30/22 | 10-Q | |
08/04/22 | 06/30/22 | 10-Q | |
05/05/22 | 03/31/22 | 10-Q | |
03/09/22 | 12/31/21 | 10-K | |
11/04/21 | 09/30/21 | 10-Q | |
08/05/21 | 06/30/21 | 10-Q | |
05/06/21 | 03/31/21 | 10-Q | |
03/25/21 | 12/31/20 | 10-K | |
11/10/20 | 09/30/20 | 10-Q | |
08/13/20 | 06/30/20 | 10-Q | |
05/22/20 | 03/31/20 | 10-Q | |
04/08/20 | 12/31/19 | 424B4 | |
11/10/20 | 09/30/19 | 10-Q | |
08/13/20 | 06/30/19 | 10-Q | |
05/22/20 | 03/31/19 | 10-Q |